Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion Leaders
VANCOUVER, British Columbia, April 19, 2022 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Ian McDonald, Chief Executive Officer, Dr. Revati Shreeniwas, Chief Medical Officer, Professor John McCorvy, PhD, Senior Advisor, and other key speakers will host a symposium on the recent therapeutic developments within the Dravet Syndrome landscape. The symposium will also include a panel with Key Opinion Leaders and a Q&A session. In addition, the Company and KOLs will also provide a developmental update on BMB-101, Bright Minds’ lead R&D program for the treatment of Dravet Syndrome.
Date: Thursday, May 19, 2022
ETWebcast Live and Replay: https://brightmindsbio.com/investors/
An archived replay of the presentation will be available on the Company’s website immediately following the conference and will be available for 90 days at: https://brightmindsbio.com/investors/.